Summary: In adults with overweight or obesity who received oral vancomycin for seven days, oral supplementation with 2′-fucosyllactose (2′-FL) for eight weeks following vancomycin treatment demonstrated significantly enhanced gut microbial resilience at two weeks and reduced fasting plasma IL-6 concentrations at eight weeks compared to placebo supplementation for eight weeks following the same vancomycin course, with no sustained differences in microbial composition or metabolic markers at end of intervention.
| PICO | Description |
|---|---|
| Population | Adults with overweight or obesity who received oral vancomycin for seven days. |
| Intervention | Oral supplementation with 2′-fucosyllactose (2′-FL), a human milk oligosaccharide, for eight weeks following vancomycin treatment. |
| Comparison | Placebo supplementation for eight weeks following the same seven-day vancomycin course. |
| Outcome | 2′-FL significantly enhanced gut microbial resilience at two weeks and reduced fasting plasma IL-6 at eight weeks. No sustained differences in microbial composition or metabolic markers at intervention end. |
2'-FL after vancomycin
RCT · overweight/obesity · 8 weeks
2'-FL after vancomycin transiently improved gut microbial resilience at 2 weeks and lowered fasting plasma IL-6 at 8 weeks versus placebo, but composition and metabolic differences were not sustained.
Clinical Context
Antibiotics save lives but disrupt the gut microbiome, sometimes with lasting consequences. Vancomycin, commonly used for Clostridioides difficile infection, is particularly devastating to gut bacteria. During recovery, patients face increased risk of recurrent infection, metabolic disturbances, and inflammation.
The connection between gut dysbiosis, obesity, and metabolic health is increasingly recognized. Individuals with obesity often have altered gut microbiome composition associated with increased gut permeability, systemic inflammation, and insulin resistance.
2′-Fucosyllactose (2′-FL) is a human milk oligosaccharide that serves as prebiotic fuel for beneficial bacteria, particularly Bifidobacteria. The rationale for 2′-FL after antibiotics is to provide selective nutrition for beneficial bacteria during the vulnerable post-antibiotic recovery period.
Clinical Pearls
1. Transient Microbiome Effect but Sustained Anti-Inflammatory Benefit: 2′-FL may have triggered early microbiome changes that initiated anti-inflammatory cascades persisting beyond the microbial effects themselves.
2. IL-6 Reduction Clinically Relevant: IL-6 is a key mediator of systemic inflammation linked to insulin resistance and cardiovascular disease.
3. Microbial Resilience as New Outcome: This study assessed how quickly the microbiome recovered toward baseline rather than just composition at endpoints.
4. Obesity May Limit Prebiotic Response: The limited sustained effects may reflect obesity-associated dysbiosis being more resistant to modification.
Practical Application
For patients who have received antibiotics, 2′-FL supplementation may offer modest benefits for microbiome recovery and inflammation reduction. Consider it as part of a broader post-antibiotic recovery strategy. Timing may matter—starting supplementation immediately after antibiotic completion may be more effective than delayed initiation.
Broader Evidence Context
Human milk oligosaccharides are an emerging area of adult nutrition research. Post-antibiotic microbiome recovery is increasingly recognized as a therapeutic target. Other approaches include probiotics, fermented foods, and diverse fiber intake.
Study Limitations
Vancomycin given to healthy volunteers creates artificial conditions. Sample size may have been insufficient to detect smaller sustained effects. Long-term outcomes and clinical relevance of transient microbiome changes remain uncertain.
Bottom Line
2′-Fucosyllactose supplementation after vancomycin transiently enhances gut microbiome recovery and reduces systemic inflammation in adults with overweight/obesity, though sustained effects were limited. May be considered as part of post-antibiotic recovery strategy.
Source: Vliex LMM, et al. “2′-Fucosyllactose supplementation results in a transient improvement in gut microbial resilience after vancomycin use.” Read article.